Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px
Organisation › Details

ADC Therapeutics S.A. (ADCT)

ADC Therapeutics SA is a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors. The Company develops ADCs by applying its decades of experience in this field and using next-generation pyrrolobenzodiazepine (PBD) technology to which ADC Therapeutics has proprietary rights for its targets. Strategic target selection for PBD-based ADCs and substantial investment in early clinical development have enabled ADC Therapeutics to build a deep clinical and research pipeline of therapies for the treatment of hematological and solid tumor cancers with significant unmet need. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase 2 clinical trials, in the USA and Europe, and numerous preclinical ADCs in development. ADCT-402, the Company’s lead product candidate, has demonstrated significant single-agent clinical activity across a broad population of patients with relapsed or refractory diffuse large B-cell lymphoma, including difficult-to-treat patients. ADCT-301, the Company’s second lead product candidate, has demonstrated clinical activity in heavily pretreated patients with Hodgkin lymphoma and, based on its mechanism of action, also has potential for the treatment of solid tumors. ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. *

 

Period Start 2012-03-26 established pred
  Group ADC Therapeutics (Group)
  Predecessor ADC Therapeutics S.a.r.l. (ADCT)
Products Industry antibody-drug conjugates (ADC) technology
  Industry 2 cancer drug
Persons Person Martin, Chris (Auven Therapeutics 201506 CEO of ADC Therapeutics before CEO of Spirogen Ltd)
  Person 2 Forer, Michael (Celtic Therapeutics 201207 CEO of ADC Therapeutics until 6/15 + Partner in Celtic Therapeutics)
     
Region Region Epalinges VD
  Country Switzerland
  Street 3B Route de la Corniche
  City 1066 Epalinges VD
  Tel +41-21-653-0200
    Address record changed: 2019-11-06
     
Basic data Employees n. a.
     
    * Document for �About Section�: ADC Therapeutics S.A.. (11/5/19). "Press Release: ADC Therapeutics Appoints Jennifer Herron as Chief Commercial Officer". Lausanne.
     
   
Record changed: 2019-11-06

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for ADC Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BIO-Europe 2019 Hamburg Germany BEU2019 650x80px




» top